Spencer Pharmaceutical Inc. Announces Dr. Michael D. Buschmann Joins the Scientific Advisory Board as New Science Assessor
23 Dezembro 2010 - 12:00PM
Marketwired
Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH), announced today the
addition of Dr. Michael D. Buschmann to the Corporation's
Scientific Advisory Board.
Dr. Buschmann has joined its Scientific Advisory Board and will
also assess new scientific opportunities for the Company.
Dr. Buschmann received a B. Engineering Physics from the
University of Saskatchewan in 1984, and a Ph.D. in Medical
Engineering and Medical Physics from the Division of Health
Sciences and Technology at the Massachusetts Institute of
Technology and Harvard University in 1992. His postdoctoral
training was then completed at the University of Bern in
Switzerland in 1994. Since 1994, he has established a
multidisciplinary research program as Professor of Biomedical
Engineering and Chemical Engineering at Ecole Polytechnique. The
program focuses on the use of biomaterials for tissue repair and
the development of polymer-based gene and drug delivery systems for
Diabetes, Cancer and Inflammatory diseases
(http://www.polymtl.ca/tissue/). Dr. Buschmann has published 90
articles, 205 conference proceedings and 13 patented or patent
pending inventions.
He is currently the Director of the FRSQ Group in Biomedical
Science and Technology and has received the Innovator Prize from
the Quebec Association for Industrial Research (ADRIQ), the
Melville Medal from the American Society of Mechanical Engineers
(ASME), and the Award of Merit from the Canadian Arthritis Network
of Centers of Excellence.
"Dr Buschmann will advise and plan product development
strategies and assess additional technologies and research that
Spencer is interested in licensing into the company. Discussions
will also continue in this sense in the coming weeks," said Dr Max
Arella, CEO of Spencer Pharmaceutical Inc. In addition "we are
confident that the experience, dedication and the vision of Dr
Buschmann will bring exciting new opportunities into our company
adding tremendous value for our shareholders," further stated Dr
Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical
Research and Development Corporation, which is developing
innovative drug release and absorption systems for the treatment of
metabolic diseases such as diabetes and metabolic syndrome.
Important Information
About Forward-Looking Statements in this
press release may be "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "anticipate," "believe," "estimate," "expect,"
"intend" and similar expressions, as they relate to the company or
its management, identify forward-looking statements. These
statements are based on current expectations, estimates and
projections about the company's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Therefore, actual
outcomes and results may, and probably will, differ materially from
what is expressed or forecasted in such forward-looking statements
due to numerous factors, including those described above. In
addition, such statements could be affected by risks and
uncertainties related to the exploration for and development of
mineralized material, product demand, market and customer
acceptance, competition, pricing and development difficulties, as
well as general industry and market conditions and growth rates and
general economic conditions. Any forward-looking statements speak
only as of the date on which they are made, and the company does
not undertake any obligation to update any forward-looking
statement to reflect events or circumstances after the date of this
release. Information on the Company's website does not constitute a
part of this release.
Contact: Dr. Max Arella President Spencer Pharmaceutical
Inc. 1+(617) 973-5017
Spencer Pharmaceutical (CE) (USOTC:SPPH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Spencer Pharmaceutical (CE) (USOTC:SPPH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024